Jimandin (Sitagliptin)

Sitagliptin selectively blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, which stimulate insulin release only when glucose is high and suppress glucagon secretion, thereby lowering plasma glucose concentrations.

The dosage of Jimandin is determined by the prescribing healthcare professional based on individual patient factors such as renal function, concomitant medications and overall treatment goals. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for sitagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Jimandin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its insulin‑stimulating effect is glucose‑dependent. Unlike metformin, it does not affect gastrointestinal absorption, and it can be combined with many other agents for additive glucose‑lowering effects.

Jimandin should be stored at ambient temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat and direct sunlight, and keep them out of reach of children.

Jimandin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a full glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

The most concerning adverse events include pancreatitis, severe allergic reactions such as anaphylaxis, and unexplained joint pain that may be disabling. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or severe arthralgia.

Jimandin is contraindicated in patients with a known hypersensitivity to sitagliptin or any of the tablet’s excipients. It should be used with caution, or avoided, in individuals with a history of pancreatitis, severe renal impairment, or significant hepatic disease, unless a prescriber decides otherwise.